Esperion Therapeutics ESPR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | -$51.75M+75.3% | -$209.25M+10.4% | -$233.66M+13.2% | ||
| $105K+66.7% | $63K-61.6% | $164K-67.2% | $500K-18.3% | ||
| $9.87M-17.7% | $11.99M+0.3% | $11.96M-21.4% | $15.22M-37.4% | ||
| $3.01M+101% | $1.5M-11.7% | $1.7M+4.7% | $1.62M0.0% | ||
| $60.05M+89.7% | $31.65M+114% | $14.77M+36.8% | $10.8M+1.0% | ||
| —— | —— | $30.42M+3,670% | $807K-95.6% | ||
| —— | —— | $8.68M+54.9% | $5.6M+116% | ||
| $31.22M+70.2% | $18.34M-17.0% | $22.1M— | —— | ||
| $30.8M+117% | $14.22M— | —— | —— | ||
| $25.96M+254% | -$16.88M-177% | $21.9M— | —— | ||
| —— | —— | -$135.49M+22.5% | -$174.83M+33.7% | ||
| $0-100% | $317K— | $0— | $0— | ||
| $0+100% | -$317K— | —— | —— | ||
| $0-100% | $99.73M— | $0— | $0— | ||
| $244K+741% | $29K+38.1% | $21K+110% | -$219K— | ||
| $36.18M— | —— | $54.77M— | —— | ||
| $23.09M— | —— | -$42.53M— | —— | ||
| $16.27M+43.4% | $11.35M+7.0% | $10.6M— | —— | ||
| $612K— | $0— | $0— | —— | ||
| $3.01M+101% | $1.5M-11.7% | $1.7M+4.7% | $1.62M0.0% | ||
| $105K+66.7% | $63K-61.6% | $164K-67.2% | $500K-18.3% | ||
| —— | —— | —— | —— | ||
| $31.22M+70.2% | $18.34M-17.0% | $22.1M— | —— | ||
| $30.8M+117% | $14.22M— | —— | —— | ||
| $57.21M+132% | $24.66M— | —— | $0— | ||
| $55.06M+111% | $26.08M— | —— | $0— | ||
| —— | $0— | $0— | —— | ||
| $72.6M-19.9% | $90.67M+72.9% | $52.43M— | $0-100% | ||
| $0-100% | $99.73M— | $0— | $0— | ||
| $244K+741% | $29K+38.1% | $21K+110% | -$219K— | ||
| $10.35M— | —— | $9.07M— | —— | ||
| $54.91M-73.9% | $210.09M— | $0— | $0— | ||
| $612K— | $0— | $0— | —— | ||
| —— | $102K-11.3% | $115K— | —— | ||
| —— | —— | -$135.49M+22.5% | -$174.83M+33.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
